SKB264 and glecirasib for advanced KRAS G12C lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new combination of two drugs (SKB264 and glecirasib) for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. It aims to see if this combination can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have advanced non-small cell lung cancer with a KRAS G12C mutation.
- You must not have had any prior treatment for advanced lung cancer (like chemotherapy, immunotherapy, or targeted therapy).
- You must be in good enough health to carry out daily activities (ECOG score 0 or 1).
- You must have at least one tumor that can be measured on scans.
- Your blood counts and organ function (kidney, liver, heart) must be within certain limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two new drugs, SKB264 and SKB118, for people with advanced non-small cell lung cancer. It may be an option if your cancer does not have the EGFR or ALK gene changes and you are in relatively good health.
This trial tests two new drugs together (sosimerasib and IN10018) as a first treatment for people with a specific type of lung cancer that has the KRAS G12C gene change. The goal is to see if the combination works better than standard therapy.
This trial tests a new combination of two medications (SKB264 and anlotinib) for people with advanced non-small cell lung cancer that has spread to the liver and no longer responds to a standard pill called an EGFR-TKI. The goal is to see if this combination can shrink tumors and help people live longer.
This trial tests a new combination of two targeted medicines for advanced non-small cell lung cancer with a specific gene change (KRAS G12C). The goal is to see if this combination can shrink or slow the cancer.
This trial tests a new pill called Garsorasib for people with advanced non-small cell lung cancer that has a specific gene change called KRAS G12C. It aims to see if the drug can shrink tumors or slow cancer growth in people who haven't had treatment yet.
This trial tests a new combination of two drugs (fulzerasib and ivonescimab) for people with a specific gene change (KRAS G12C) in their advanced lung cancer. It aims to see if this combination is safe and effective as the first treatment for this type of cancer.
Hear when a new NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.